ea0099rc12.2 | Rapid Communications 12: Diabetes, Obesity, Metabolism and Nutrition | Part II | ECE2024
Tzoulis Ploutarchos
, Batavanis Michael
Introduction: The prevalence of obesity, a chronic disease with significant morbidity, has rapidly increased in recent decades. Semaglutide, an injectable glucagon-like peptide-1 agonist, has gained global popularity after its approval for weight management in 2021. All studies have reported marked variability in semaglutide response, with a small proportion of patients (10-16%) showing inadequate response. Data about the predictors of poor response to semaglutide for weight l...